SARomics Biostructures and Vipergen Offer DEL-based drug discovery services
SARomics Biostructures AB and Vipergen ApS partner to offer hit and lead identification services based on Vipergen’s DEL screening technology.
SARomics Biostructures AB and Vipergen ApS partner to offer hit and lead identification services based on Vipergen’s DEL screening technology.
In this article, we discuss weak affinity chromatography (WAC™), the proprietary fragment screening technique jointly owned by SARomics Biostructures and Red Glead Discovery.
In this article, we will discuss some significant publications and company activities in 2023. The publications showcase our expertise in the three main areas of our services: X-ray crystallography, NMR spectroscopy, and integrated drug discovery.
In this post we want to bring to the attention of our readers the revival of room-temperature (RT) protein crystallography using synchrotron radiation and its potential applications in structure-based drug design to study of functionally-important conformations.
In this third post on structural biology and structure-based drug design we discuss fragment libraries and fragment-based lead discovery
Which strategy to choose when planning a drug discovery project? Maybe structure-based design, ligand-based design, or de novo design? These questions are discussed in our series on structure-based drug design in this second post.
Applying structural biology methods requires many different skills and experience. A structural biology services company technology platform brings together all experimental methods and people with the skills required to run a structure-based drug discovery project.
Several private and public organizations join efforts in the LundaGUARD consortium to respond to present and future threats from infectious…